insights_auto
Why is GIFLF down ၅.၂၄%?
Dive Deeperchevron_right
GIFLF:OTCMKTS
Grifols SA Class A
၁၀.၅၅ US$
arrow_downward
-၅.၂၄%(-၀.၅၈) 1D
အောက် ၁၃, GMT-၄ ၁၆:၀၀:၀၀ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GIFLF...
Open
၁၀.၅၅ US$
High
၁၀.၅၅ US$
Low
၁၀.၅၅ US$
Mkt. cap
၆၆၂.၈၅ ဋေ
Avg. vol.
၅၄၃.၀၀
Volume
၉.၇၀ ထောင်
52-wk high
၁၂.၉၀ US$
52-wk low
၁၀.၁၃ US$
Beta
၀.၉၀
Shares outstanding
၄၂.၆၁ ကုဋေ
No. of employees
၂ သောင်း
Open
၁၀.၅၅ US$
High
၁၀.၅၅ US$
Low
၁၀.၅၅ US$
Mkt. cap
၆၆၂.၈၅ ဋေ
Avg. vol.
၅၄၃.၀၀
Volume
၉.၇၀ ထောင်
52-wk high
၁၂.၉၀ US$
52-wk low
၁၀.၁၃ US$
Beta
၀.၉၀
Shares outstanding
၄၂.၆၁ ကုဋေ
No. of employees
၂ သောင်း
News stories
From web sources and news partners
MarketBeat
·
ပြီးခဲ့သည့် ၉ နာရီ
Grifols, S.A. (NASDAQ:GRFS) Shares Shorted: Short Interest Up 105.0% in September
ad-hoc-news.de
·
ပြီးခဲ့သည့် ၁ ရက်
Wall Street Zen downgrades Grifols stock from Buy to Hold
Profile
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
About Grifols SA Class A